COX-1 Inhibitors: Beyond Structure Toward Therapy

Medicinal Research Reviews

Volumn 36, Issue 4, 2016, Pages 641-671

  Vitale, Paola ^a   Panella, Andrea ^a   Scilimati, Antonio ^a   Perrone, Maria Grazia ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

COX 1 inhibitors; docking studies; natural compounds and dietary phytochemicals; neuroinflammation; ovarian cancer

Indexed keywords

BENZAMIDE DERIVATIVE; CANNABINOID; CARBOXYLIC ACID; CURCUMINOID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; FLAVONOID; ISOXAZOLE DERIVATIVE; PLANT EXTRACT; PYRAZOLE DERIVATIVE; RUMEX NEPALENSIS EXTRACT; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER GROWTH; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MOLECULAR DOCKING; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; REVIEW; RUMEX NEPALENSIS; TUMOR MICROENVIRONMENT;

EID: 84974678249     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21389     Document Type: Review

References (64)

1. Perrone MG, Scilimati A, Simone L, Vitale P. Selective COX-1 inhibition: A therapeutic target to be reconsidered. Curr Med Chem 2010;17(32):3769–3805.
2. Perrone MG, Vitale P, Panella A, Fortuna CG, Scilimati A. General role of the amino and methylsulfamoyl groups in selective cyclooxygenase(COX)-1 inhibition by 1,4-diaryl-1,2,3-triazoles and validation of a predictive pharmacometric PLS model. Eur J Med Chem 2015;94:252–264.
3. Regulski M, Regulska K, Prukała W, Piotrowska H, Stanisz B, Murias M. COX-2 inhibitors: A novel strategy in the management of breast cancer. Drug Discov Today 2015;pii:S1359-6446(15)00455-459.
4. Asghar W, Jamali F. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: A systematic review. Inflammopharmacology 2015;23(1):1–16.
5. Patrignani P, Patrono C. Cyclooxygenase inhibitors: From pharmacology to clinical read-outs. Biochim Biophys Acta 2015;1851(4):422–432.
6. Thompson HJ, Jiang C, Lu J, Mehta RG, Piazza GA, Paranka NS, Pamukcu R, Ahnen DJ. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res 1997;57(2):267–271
7. Reddy BS, Kawamori T, Lubet RA, Steele VE, Kelloff GJ, Rao CV. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. Cancer Res 1999;59(14):3387–3391.
8. Liedtke AJ, Crews BC, Daniel CM, Blobaum AL, Kingsley PJ, Ghebreselasie K, Marnett LJ. Cyclooxygenase-1-selective inhibitors based on the (E)-2′-Des-methyl-sulindac sulfide scaffold. J Med Chem 2012;55(5):2287–2300.
9. Felts AS, Ji C, Stafford JB, Crews BC, Kingsley PJ, Rouzer CA, Washington MK, Subbaramaiah K, Siegel BS, Young SM, Dannenberg AJ, Marnett LJ. Desmethyl derivatives of indomethacin and sulindac as probes for cyclooxygenase-dependent biology. ACS Chem Biol 2007;2(7): 479–483.
10. Vitale P, Scilimati A, Perrone MG. Update on SAR studies toward new COX-1 selective inhibitors. Curr Med Chem 2015;22(37):4271–4292.
11. Goto K, Ochi H, Yasunaga Y, Matsuyuki H, Imayoshi T, Kusuhara H, Okumoto T. Analgesic effect of mofezolac, a non-steroidal anti-inflammatory drug, against phenylquinone-induced acute pain in mice A new antiinflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins Other Lipid Mediat 1998;56(4):245–254.
12. Di Nunno L, Vitale P, Scilimati A, Tacconelli S, Patrignani P. Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: Reversal cyclooxygenase-2 selectivity by sulfonamide group removal. J Med Chem 2004;47(20):4881–4890.
13. Vitale P, Tacconelli S, Perrone MG, Malerba P, Simone L, Scilimati A, Lavecchia A, Dovizio M, Marcantoni E, Bruno A, Patrignani P. Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors. J Med Chem 2013;56(11):4277–4299.
14. Vitale P, Perrone MG, Malerba P, Lavecchia A, Scilimati A. Selective COX-1 inhibition as a target of theranostic novel diarylisoxazoles. Eur J Med Chem 2014;74:606–618.
15. Perrone MG, Vitale P, Malerba P, Altomare A, Rizzi R, Lavecchia A, Di Giovanni C, Novellino E, Scilimati A. Diarylheterocycle core ring features effect in selective COX-1 inhibition. ChemMedChem 2012;7(4):629–641.
16. Imanishi J, Morita Y, Yoshimi E, Kuroda K, Masunaga T, Yamagami K, Kuno M, Hamachi E, Aoki S, Takahashi F, Nakamura K, Miyata S, Ohkubo Y, Mutoh S. Pharmacological profile of FK881(ASP6537), a novel potent and selective cyclooxygenase-1 inhibitor. Biochem Pharmacol 2011;82(7):746–754.
17. Kakuta H, Zheng X, Oda H, Harada S, Sugimoto Y, Sasaki K, Tai A. Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. Design and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 selective inhibitor. J Med Chem 2008;51(8):2400–2411.
18. Kakuta H, Fukai R, Xiaoxia Z, Ohsawa F, Bamba T, Hirata K, Tai A. Identification of urine metabolites of TFAP, a cyclooxygenase-1 inhibitor. Bioorg Med Chem Lett 2010;20(6):1840–1843.
19. Fukai R, Zheng X, Motoshima K, Kakuta H. Significance and creation of novel cyclooxygenase-1 (COX-1) selective inhibitors. J Pharm Soc Jpn 2011;131(3):347–351.
20. Shi L, Li ZL, Yang Y, Zhu ZW, Zhu HL. Design of novel N-phenylnicotinamides as selective cyclooxygenase-1 inhibitors. Bioorg Med Chem Lett 2011;21(1):121–124.
21. Perrone MG, Malerba P, Uddin MJ, Vitale P, Panella A, Crews BC, Daniel CK, Ghebreselasie K, Nickels M, Tantawy MN, Manning HC, Marnett LJ, Scilimati A. PET radiotracer [¹⁸F]-P6 selectively targeting COX-1 as a novel biomarker in ovarian cancer: Preliminary investigation. Eur J Med Chem 2014;80:562–568.
22. Evangelista V, Manarini S, Di Santo A, Capone ML, Ricciotti E, Di Francesco L, Tacconelli S, Sacchetti A, D'Angelo S, Scilimati A, Sciulli MG, Patrignani P. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. Circ Res 2006;98(5):593–595.
23. Balaji B, Hariharan S, Shah DB, Ramanathan M. Discovery of potential and selective COX-1 inhibitory leads using pharmacophore modelling, in silico screening and in vitro evaluation. Eur J Med Chem 2014;86:469–480.
24. Zhang Y, Shi S, Chen X, Peng M. Functionalized magnetic nanoparticles coupled with mass spectrometry for screening and identification of cyclooxygenase-1 inhibitors from natural products. J Chrom B Anal Technol Biomed Life Sci 2014;960:126–132.
25. Cao H, Yu R, Choi Y, Ma ZZ, Zhang H, Xiang W, Lee DY, Berman BM, Moudgil KD, Fong HH, van Breemen RB. Discovery of cyclooxygenase inhibitors from medicinal plants used to treat inflammation. Pharmacol Res 2010;61(6):519–524.
26. Jachak SM, Gautam R, Selvam C, Madhan H, Srivastava A, Khan T. Anti-inflammatory, cyclooxygenase inhibitory and antioxidant activities of standardized extracts of Tridax procumbens L. Fitoterapia 2011;82(2):173–177.
27. Valdés-Barrera ID, Cuca-Suarez LE, Coy-Barrera ED. Nectandra amazonum-derived flavonoids as COX-1 inhibitors: In vitro and docking studies. Nat Prod Commun 2014;9(5):649–652.
28. Jeppesen AS, Soelberg J, Jäger A. Antibacterial and COX-1 inhibitory effect of medicinal plants from the Pamir Mountains, Afghanistan. Plants 2012;1:74–81.
29. Li H, Zhu F, Sun Y, Li B, Oi N, Chen H, Lubet RA, Bode AM, Dong Z. Select dietary phytochemicals function as inhibitors of COX-1 but not COX-2. PLoS One 2013;8(10):e76452.
30. Ruhaak LR, Felth J, Karlsson PC, Rafter JJ, Verpoorte R, Bohlin L. Evaluation of the cyclooxygenase inhibiting effects of six major cannabinoids isolated from Cannabis sativa. Biol Pharm Bull 2011;34(5):774–778.
31. Kozak KR, Rowlinson SW, Marnett LJ. Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. J Biol Chem 2000;275(43):33744–33749.
32. Yu M, Ives D, Ramesha CS. Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem 1997;272(34):21181–21186.
33. Takeda S, Misawa K, Yamamoto I, Watanabe K. Cannabidiolic acid as a selective cyclooxygenase-2 inhibitory component in cannabis. Drug Metab Dispos 2008;36(9):1917–1921.
34. Radziwon-Balicka A, Moncada de la Rosa C, Jurasz P. Platelet-associated angiogenesis evaulating factors: A pharmacological perspective. Can J Physiol Pharmacol 2012;90(6):679–688.
35. Goubran HA, Burnouf T, Radosevic M, El-Ekiaby M. The platelet-cancer loop. Eur J Intern Med 2013;24(5):393–400.
36. Fang H, Declerck YA. Targeting the tumor microenvironment: From understanding pathways to effective clinical trials. Cancer Res 2013;73(16):4965–4977.
37. Bar EE, Lin A, Mahairaki V, Matsui W, Eberhart CG. Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am J Pathol 2010;177(3):1491–1502.
38. Tsai YP, Wu KJ. Hypoxia-regulated target genes implicated in tumor metastasis. J Biomed Sci 2012;14(19):102
39. Rossi Sartori-Cintra A, Sampaia de Mara C, Argolo DL, Bellini Coimbra I. Regulation of hypoxia-inducible factor-1a (HIF-1a) expression by interleukin-1b (IL-1b), insulin-like growth factors I (IGF-I) and II (IGF-II) in human osteoarthritic chondrocytes. Clinics (Sao Paulo) 2012;67(1):35–40.
40. Kumar A, Vishvakarma NK, Tyagi A, Bharti AC, Singh SM. Anti-neoplastic action of aspirin against a T-cell lymphoma involves an alteration in the tumour microenvironment and regulation of tumour cell survival. Biosci Rep 2012;32(1):91–104.
41. Su BB, Chen JH, Shi H, Chen QQ, Wan J. Aspirin may modify tumor microenvironment via antiplatelet effect. Med Hypotheses 2014;83:148–150.
42. Yu M, Ting DT, Stott SL, Wittner BS, Ozsolak F, Paul S, Ciciliano JC, Smas ME, Winokur D, Gilman AJ, Ulman MJ, Xega K, Contino G, Alagesan B, Brannigan BW, Milos PM, Ryan DP, Sequist LV, Bardeesy N, Ramaswamy S, Toner M, Maheswaran S, Haber DA. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature 2012;487(7408):510–513.
43. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 2011;20(5):576–590.
44. Bao B, Wang Z, Ali S, Kong D, Li Y, Ahmad A, Banerjee S, Azmi AS, Miele L, Sarkar FH. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett 2011;307(1):26–36.
45. Gotzmann J, Fischer AN, Zojer M, Mikula M, Proell V, Huber H, Jechlinger M, Waerner T, Weith A, Beug H, Mikulits W. A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes. Oncogene 2006;25(22):3170–3185.
46. Lou XL, Deng J, Deng H, Ting Y, Zhou L, Liu YH, Hu JP, Huang XF, Qi XQ. Aspirin inhibit platelet-induced epithelial-to-mesenchymal transition of circulating tumor cells. Biomed Rep 2014;2(3):331–334.
47. Wilson AJ, Fadare O, Beeghly-Fadiel A, Son DS, Liu Q, Zhao S, Saskowski J, Uddin MJ, Daniel C, Crews B, Lehmann BD, Pietenpol JA, Crispens MA, Marnett LJ, Khabele D. Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. Oncotarget 2015;6(25):21353–21368.
48. Uddin MJ, Elleman AV, Ghebreselasie K, Daniel CK, Crews BC, Nance KD, Huda T, Marnett LJ. Design of fluorine-containing 3,4-diarylfuran-2(5H)-ones as selective COX-1 inhibitors. ACS Med Chem Lett 2014;5(11):1254–1258.
49. Perrone MG, Vitale P., Panella A, Ferorelli S, Contino M, Lavecchia A, Scilimati A. Isoxazole-based scaffold inhibitors targeting cyclooxygenase(COX)s. Chem Med Chem, 2016 in press.
50. Lee JP, Hahn HS, Hwang SJ, Choi JY, Park JS, Lee IH, Kim TJ. Selective cyclooxygenase inhibitors increase paclitaxel sensitivity in taxane-resistant ovarian cancer by suppressing P-glycoprotein expression. J Gynecol Oncol 2013;24(3):273–279.
51. Yermakova AV, Rollins J, Callahan LM, Rogers J, O'Banion MK. Cyclooxygenase-1 in human Alzheimer and control brain: Quantitative analysis of expression by microglia and CA3 hippocampal neurons. J Neuropathol Exp Neurol 1999;58(11):1135–1146.
52. Aïd S, Bosetti F. Gene expression of cyclooxygenase-1 and Ca(2+)-independent phospholipase A(2) is altered in rat hippocampus during normal aging. Brain Res Bull 2007;73(1–3):108–113.
53. Barrio JR1, Satyamurthy N, Huang SC, Petric A, Small GW, Kepe V. Dissecting molecular mechanisms in the living brain of dementia patients. Acc Chem Res 2009;42(7):842–850.
54. Choi SH, Aid S, Bosetti F. The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: Implications for translational research. Trends Pharmacol Sci 2009;30:174–181.
55. Choi SH, Langenbach R, Bosetti F. Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury. FASEB J 2008;22:1491–501.
56. Calvello R, Panaro MA, Carbone ML, Cianciulli A, Perrone MG, Vitale P, Malerba P, Scilimati A. Novel selective COX-1 inhibitors suppress neuroinflammatory mediators in LPS-stimulated N13 microglial cells. Pharmacol Res 2012;65:137–148.
57. Choi SH, Aid S, Choi U, Bosetti F. Cyclooxygenases-1 and -2 differentially modulate leukocyte recruitment into the inflamed brain. Pharmacogenomics J 2010;10:448–457.
58. Russo I, Amornphimoltham P, Weigert R, Barlati S, Bosetti F. Cyclooxygenase-1 is involved in the inhibition of hippocampal neurogenesis after lipopolysaccharide-induced neuroinflammation. Cell Cycle 2011;10:2568–2573.
59. Wallace JL, Bell CJ. Gastroduodenal mucosal defence. Curr Opin Gastroenterol 1996;12:503–511.
60. Jackson LM1, Wu KC, Mahida YR, Jenkins D, Hawkey CJ. Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa. Gut 2000;47(6):762–770.
61. Haworth R, Oakley K, McCormack N, Pilling A. Differential expression of COX-1 and COX-2 in the gastrointestinal tract of the rat. Toxicol Pathol 2005;33(2):239–245.
62. Hiratsuka T, Futagami S, Tatsuguchi A, Suzuki K, Shinji Y, Kusunoki M, Shinoki K, Nishigaki H, Fujimori S, Wada K, Miyake K, Gudis K, Tsukui T, Sakamoto C. COX-1 and COX-2 conversely promote and suppress ischemia-reperfusion gastric injury in mice. Scand J Gastroenterol 2005;40(8):903–913.
63. Perrone MG, Lofrumento DD, Vitale P, De Nuccio F, La Pesa V, Panella A, Calvello R, Cianciulli A, Panaro MA, Scilimati A. Selective cyclooxygenase-1 inhibition by P6 and gastrotoxicity: Preliminary investigation. Pharmacology 2015;95(1–2):22–28.
64. Tanaka A, Araki H, Hase S, Komoike Y, Takeuchi K. Up-regulation of COX-2 by inhibition of COX-1 in the rat: A key to NSAID-induced gastric injury. Aliment Pharmacol Ther 2002;16(2):90–101.